Ironwood Pharmaceuticals Reports Second Quarter 2022 Results; Maintains Full Year Guidance Due to Continued Strength of LINZESS® Prescription Demand

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/22/2026

1. SPCX
2. NVDA
3. ACN
4. USO
5. DFTX
6. GOOGL
7. APGE
8. MU
9. IBM
10. HOOD

Go back to Ironwood Pharmaceuticals Reports Second Quarter 2022 Results; Maintains Full Year Guidance Due to Continued Strength of LINZESS® Prescription Demand

Ironwood Pharma (IRWD) Misses Q2 EPS by 12c; Reiterates Outlook

August 4, 2022 7:37 AM EDT

Ironwood Pharma (NASDAQ: IRWD) reported Q2 EPS of $0.21, $0.12 worse than the analyst estimate of $0.33. Revenue for the quarter came in at $97.23 million versus the consensus estimate of $103.55 million.

GUIDANCE:

Ironwood Pharma reiterates FY2022 revenue of $420-$430 million, versus the consensus of... More